{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:33:09Z","timestamp":1763141589723,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40801-021-00251-w","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T19:02:40Z","timestamp":1623870160000},"page":"497-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-1797","authenticated-orcid":false,"given":"Leorah","family":"Freeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Kee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rina","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"issue":"1","key":"251_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","volume":"20","author":"JA Nicholas","year":"2020","unstructured":"Nicholas JA, Edwards NC, Edwards RA, Dellarole A, Grosso M, Phillips AL. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):281.","journal-title":"BMC Neurol."},{"issue":"Suppl 1","key":"251_CR2","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S0022-510X(09)70012-7","volume":"277","author":"P Rieckmann","year":"2009","unstructured":"Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(Suppl 1):S42\u20135.","journal-title":"J Neurol Sci."},{"issue":"10","key":"251_CR3","doi-asserted-by":"publisher","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","volume":"92","author":"MT Wallin","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029\u201340.","journal-title":"Neurology"},{"issue":"Suppl 6","key":"251_CR4","first-page":"S141","volume":"22","author":"SF Hunter","year":"2016","unstructured":"Hunter SF. Overview and diagnosis of multiple sclerosis. Am J Manag Care. 2016;22(Suppl 6):S141\u201350.","journal-title":"Am J Manag Care."},{"issue":"2","key":"251_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00415-008-0743-8","volume":"255","author":"C Hirst","year":"2008","unstructured":"Hirst C, Ingram G, Pearson O, Pickersgill T, Scolding N, Robertson N. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008;255(2):280\u20137.","journal-title":"J Neurol."},{"issue":"11","key":"251_CR6","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1212\/01.WNL.0000096175.39831.21","volume":"61","author":"FD Lublin","year":"2003","unstructured":"Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61(11):1528\u201332.","journal-title":"Neurology"},{"issue":"5","key":"251_CR7","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.apmr.2013.10.032","volume":"95","author":"VY Ma","year":"2014","unstructured":"Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014;95(5):986-95.e1.","journal-title":"Arch Phys Med Rehabil."},{"issue":"1\u20132","key":"251_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2013.04.007","volume":"330","author":"H Parise","year":"2013","unstructured":"Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, et al. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci. 2013;330(1\u20132):71\u20137.","journal-title":"J Neurol Sci."},{"issue":"6 Suppl","key":"251_CR9","first-page":"s151","volume":"22","author":"GM Owens","year":"2016","unstructured":"Owens GM. Economic burden of multiple sclerosis and the role of managed care organizations in multiple sclerosis management. Am J Manag Care. 2016;22(6 Suppl):s151\u20138.","journal-title":"Am J Manag Care."},{"issue":"17","key":"251_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"key":"251_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4137\/PMC.S13213","volume":"6","author":"A Finkelsztejn","year":"2014","unstructured":"Finkelsztejn A. Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem. 2014;6:65\u201372.","journal-title":"Perspect Medicin Chem."},{"key":"251_CR12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/CEOR.S130334","volume":"9","author":"J Burks","year":"2017","unstructured":"Burks J, Marshall TS, Ye X. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEcon Outcomes Res. 2017;9:251\u201360.","journal-title":"ClinicoEcon Outcomes Res."},{"issue":"1","key":"251_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ncl.2020.09.002","volume":"39","author":"C Goldschmidt","year":"2021","unstructured":"Goldschmidt C, McGinley MP. Advances in the treatment of multiple sclerosis. Neurol Clin. 2021;39(1):21\u201333.","journal-title":"Neurol Clin."},{"key":"251_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PPA.S8230","volume":"4","author":"F Patti","year":"2010","unstructured":"Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1\u20139.","journal-title":"Patient Prefer Adherence."},{"issue":"7","key":"251_CR15","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s12325-020-01367-1","volume":"37","author":"J Bowen","year":"2020","unstructured":"Bowen J, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, et al. Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy. Adv Ther. 2020;37(7):3163\u201377.","journal-title":"Adv Ther."},{"issue":"6","key":"251_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neurol.2018.04.004","volume":"174","author":"E Le Page","year":"2018","unstructured":"Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174(6):449\u201357.","journal-title":"Rev Neurol (Paris)."},{"issue":"1","key":"251_CR17","first-page":"113","volume":"25","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Mahesri M, Gagne JJ, Hurley E, Tong A, Chitnis T, et al. Utilization patterns of oral disease-modifying drugs in commercially insured patients with multiple sclerosis. J Manag Care Spec Pharm. 2019;25(1):113\u201321.","journal-title":"J Manag Care Spec Pharm."},{"issue":"8","key":"251_CR18","first-page":"844","volume":"23","author":"KM Johnson","year":"2017","unstructured":"Johnson KM, Zhou H, Lin F, Ko JJ, Herrera V. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23(8):844\u201352.","journal-title":"J Manag Care Spec Pharm."},{"key":"251_CR19","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.msard.2018.11.004","volume":"27","author":"S Setayeshgar","year":"2019","unstructured":"Setayeshgar S, Kingwell E, Zhu F, Zhang T, Carruthers R, Marrie RA, et al. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: a population-based study. Mult Scler Relat Disord. 2019;27:364\u20139.","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"251_CR20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/WCO.0000000000000700","volume":"32","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Mares J, Hartung HP. Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm. Curr Opin Neurol. 2019;32(3):365\u201377.","journal-title":"Curr Opin Neurol."},{"issue":"10","key":"251_CR21","doi-asserted-by":"publisher","first-page":"e1016","DOI":"10.1212\/WNL.0000000000007043","volume":"92","author":"WJ Culpepper","year":"2019","unstructured":"Culpepper WJ, Marrie RA, Langer-Gould A, Wallin MT, Campbell JD, Nelson LM, et al. Validation of an algorithm for identifying MS cases in administrative health claims datasets. Neurology. 2019;92(10):e1016\u201328.","journal-title":"Neurology"},{"issue":"6","key":"251_CR22","doi-asserted-by":"publisher","first-page":"469","DOI":"10.18553\/jmcp.2002.8.6.469","volume":"8","author":"DA Ollendorf","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469\u201376.","journal-title":"J Manag Care Pharm."},{"issue":"4","key":"251_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3111\/13696998.2010.523670","volume":"13","author":"BJ Chastek","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618\u201325.","journal-title":"J Med Econ."},{"key":"251_CR24","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2147\/PPA.S115090","volume":"11","author":"M Tintor\u00e9","year":"2017","unstructured":"Tintor\u00e9 M, Alexander M, Costello K, Duddy M, Jones DE, Law N, et al. The state of multiple sclerosis: current insight into the patient\/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33\u201345.","journal-title":"Patient Prefer Adherence."},{"issue":"6","key":"251_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.7224\/1537-2073.2017-070","volume":"20","author":"A Ben-Zacharia","year":"2018","unstructured":"Ben-Zacharia A, Adamson M, Boyd A, Hardeman P, Smrtka J, Walker B, et al. Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. Int J MS Care. 2018;20(6):287\u201397.","journal-title":"Int J MS Care."},{"issue":"10","key":"251_CR26","doi-asserted-by":"publisher","first-page":"e22108","DOI":"10.2196\/22108","volume":"8","author":"A Pratap","year":"2020","unstructured":"Pratap A, Grant D, Vegesna A, Tummalacherla M, Cohan S, Deshpande C, et al. Evaluating the utility of smartphone-based sensor assessments in persons with multiple sclerosis in the real-world using an app (elevateMS): observational, prospective pilot digital health study. JMIR mHealth uHealth. 2020;8(10):e22108.","journal-title":"JMIR mHealth uHealth."},{"issue":"6","key":"251_CR27","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.msard.2014.09.002","volume":"3","author":"K O'Connell","year":"2014","unstructured":"O\u2019Connell K, Kelly SB, Fogarty E, Duggan M, Buckley L, Hutchinson M, et al. Economic costs associated with an MS relapse. Mult Scler Relat Disord. 2014;3(6):678\u201383.","journal-title":"Mult Scler Relat Disord."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-021-00251-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-021-00251-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T05:09:33Z","timestamp":1637384973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-021-00251-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["251"],"URL":"https:\/\/doi.org\/10.1007\/s40801-021-00251-w","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"type":"print","value":"2199-1154"},{"type":"electronic","value":"2198-9788"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"19 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Bristol Myers Squibb, Princeton, NJ, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Leorah Freeman has received consultancy fees from Celgene and Biogen; has received program sponsorship from Biogen and EMD Serono; and has participated on advisory boards for Genentech, Novartis, Celgene, and EMD Serono. Arianna Kee is employed by Bristol Myers Squibb. Marc Tian and Rina Mehta were employed by Celgene, a Bristol Myers Squibb company, at the time the study was conducted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Potential conflicts of interests\/Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"BMS policy on data sharing may be found at\u00a0.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors were involved in the design and conduction of the study, as well as in drafting the manuscript and revising it critically for intellectual content. All authors had access to the data and interpreted the data and agree to be accountable for all aspects of the work related to the accuracy and integrity of any part of the work. All authors have approved the final version for submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}